RESOURCES
-
-
-
February 09, 2026
GemPharmatech Mouse Models Support Discovery in Cell Publication: Revealing a Novel Treg-Mediated Mechanism of Immunotherapy Resistance
GemPharmatech’s models were used in a publication accepted by the prestigious journal Cell. The study reveals a fundamental new mechanism of tumor immune evasion. It demonstrates that tumor-produced ammonia is metabolically utilized by regulatory T cells (Tregs), enhancing their immunosuppressive capacity and driving resistance to treatment. In cancer immunotherapy, understanding how metabolic byproducts in the tumor microenvironment (TME) influence immune cells is a central focus. Read the blog to learn how GemPharmatech's mouse models were instrumental in this research.
-
-
-
-
January 29, 2026
Advancing PVR Research: A Novel Transgenic Mouse Model with Spontaneous Disease Phenotype
Proliferative Vitreoretinopathy (PVR) is the formation of scar tissue in the eye after complication of retinal detachment or eye injury. At present, the therapeutic approaches for PVR are limited, with surgery still serving as the core treatment. Based on years of experience in transgenic mouse research and development, GemPharmatech has developed a novel B6-Rho-hVEGFA-Tg transgenic mouse model. By 4 weeks of age, it exhibits typical ocular pathological features, including abnormal retinal neovascularization, retinal structural detachment, and formation of proliferative membranes, thereby serving as a novel tool for research on proliferative vitreoretinopathy (PVR) and other related neovascular ophthalmic diseases.
-
-
-
-
December 15, 2025
Fabry Disease Mouse Models for Preclinical Efficacy Evaluation
Fabry disease (FD) is a rare, progressive, X-linked inherited disorder caused by deficient or absent lysosomal α-galactosidase A (α-GAL) activity, leading to impaired glycosphingolipid metabolism. To accelerate FD research and help researchers better understand disease mechanisms and develop new treatments, GemPharmatech has developed two GLA gene knockout mouse models: Gla-KO and NCG-Gla-KO.
-
-
-
-
December 11, 2025
A Novel Mouse Model of Atherosclerosis for Testing PCSK9-Targeted Therapeutics
Atherosclerosis is pathologically characterized by the subendothelial buildup of lipids, extracellular matrix, and cholesterol-laden macrophages, which collectively form atherosclerotic plaques. The liver-secreted protein PCSK9 promotes the lysosomal degradation of the hepatic LDL receptor (LDLR) through direct binding. This process impairs LDL clearance and elevates circulating LDL-C (low-density lipoprotein cholesterol), a central driver in the pathogenesis of atherosclerosis. Consequently, this pathophysiological pathway establishes PCSK9 as a validated therapeutic target for treating atherosclerosis.
-
-
-
-
November 17, 2025
Immune-Related Cytotoxicity Evaluation Platform for In Vitro Pharmacodynamics
Antibody drugs exert antitumor effects by regulating immune function. Their core mechanism lies in specific binding to antigens on the surface of tumor cells, enabling precise killing of tumor cells in synergy with immune cells. In this process, the Fc region of antibodies mainly relies on three key effector functions—ADCC, ADCP, and CDC—which together form the antibody-mediated antitumor immune network. This article introduces GemPharmatech’s in vitro immune-related cytotoxicity evaluation platform and illustrates its capabilities through a series of case studies that show how each mechanism is measured, compared, and applied in drug development.
-
-
-
-
November 10, 2025
Preclinical Mouse Models for Reliable ALS Therapeutic Insights
Amyotrophic Lateral Sclerosis (ALS), often known as Lou Gehrig's disease, is the third most prevalent neurodegenerative disorder worldwide. It relentlessly targets motor neurons in the brain and spinal cord, leading to progressive muscle weakness, paralysis, and ultimately, respiratory failure. For the hundreds of thousands of patients and families it affects globally, every new research breakthrough brings new hope for finding a cure.
-
-
-
-
November 04, 2025
Advancing Novel Breast Cancer Drug Development with HER2-ADC Resistance Models
According to data from the World Health Organization (WHO), breast cancer is the second most commonly diagnosed cancer globally, after lung cancer, and remains the leading cause of cancer incidence and mortality among women.
-
-
-
-
October 27, 2025
Evaluating CD20 Antibody Efficacy Using BAFF/CD20 Dual-Target Humanized Mice
B-cell–driven autoimmune diseases such as systemic lupus erythematosus (SLE) and rheumatoid arthritis are characterized by overactive B-cell signaling, autoantibody production, and chronic inflammation. CD20, a B-cell surface marker critical for activation and differentiation, has emerged as a key therapeutic target in these disorders. Antibodies that deplete B-cells, such as Rituximab, have demonstrated strong clinical efficacy, but preclinical evaluation requires models that faithfully replicate human immune biology.
-
-
-
-
October 12, 2025
Accelerating Anti-Myopathy Drug Discovery: A Dexamethasone-Induced Sarcopenia Model for Preclinical Evaluation
Sarcopenia, the progressive loss of skeletal muscle mass and function, is a major contributor to frailty, falls and chronic morbidity in aging populations. Beyond physical decline, sarcopenia increases susceptibility to cardiovascular, respiratory, and cognitive disorders, significantly impacting the quality of life and mortality. Despite its growing prevalence, no FDA-approved pharmacological therapy currently exist for sarcopenia. Preclinical animal models are essential for understanding disease mechanisms and evaluating therapeutic candidates, but traditional models such as aged or genetically modified mice require long study timelines and often show high variability.
-